<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04195035</url>
  </required_header>
  <id_info>
    <org_study_id>S-19-2019</org_study_id>
    <nct_id>NCT04195035</nct_id>
  </id_info>
  <brief_title>Comparison of Air QTM Intubating Airway Versus Ambu-Aura Intubating Laryngeal Mask</brief_title>
  <official_title>Comparison of Air QTM Intubating Airway Versus Ambu-Aura Intubating Laryngeal Mask Obese Patients Under General Anaesthesia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Supraglottic airway devices are important tools for airway management. Supraglottic airway
      devices have been introduced into brief surgical interventions because they are less invasive
      than intubation and safer than mask to maintain the patency of airway after induction of
      anesthesia. They are inserted via the oral route and can be used in emergency conditions when
      tracheal intubation and mask anesthesia are challenging.

      Air Q intubating airway and Ambu Aura intubating laryngeal mask are two Supraglottic airway
      devices that are widely used.

      Aim of the work is to compare Air-Q intubating laryngeal airway versus Ambu-Aura intubating
      laryngeal mask regarding sealing pressure and Fiberoptic intubation in class II obese
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized comparative trial that will be performed in Kasr Al Ainy hospital, Cairo
      University, Cairo, Egypt.ASA II patients from 20 to 50 years of age, undergoing minor surgry
      were included in this study. 40 patients will be allocated into 2 equal groups using
      computerized software and enclosed in sealed opaque envelopes:

      GQ ( n=20 ): Where Air-Q intubating laryngeal airway will be used for ventilation &amp;
      intubation through fiberoptic bronchoscope.

      GA ( n=20 ): Where Ambu-Aura intubating laryngeal mask will be used for ventilation &amp;
      intubation through fiberoptic bronchscope.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">January 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>airway seal pressure</measure>
    <time_frame>1 minute</time_frame>
    <description>Measuring the seal pressure above which the oropharyngeal leak through the supraglottic device will occur (1 minute after confirmation of successful insertion).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success rate</measure>
    <time_frame>1 minute</time_frame>
    <description>Success rate of device insertion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial blood pressure</measure>
    <time_frame>2 hours</time_frame>
    <description>systolic and diastolic arterial blood pressure. • Stress response related to the device used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>2 hours</time_frame>
    <description>• Stress response related to the device used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laryngeal view grade.</measure>
    <time_frame>1 minute</time_frame>
    <description>Grade 1: only larynx was seen, Grade 2: larynx plus the posterior surface of epiglottis were seen. Grade 3: larynx and anterior tip of epiglottis were seen with &lt;50% visual obstruction of larynx.
Grade 4: epiglottis down folded and its anterior surface were seen with &gt;50% visual field obstruction.
Grade 5: complete down folding of epiglottis and the larynx could not be seen directly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate of intubation by fiberoptic bronchoscope</measure>
    <time_frame>1 minute</time_frame>
    <description>The success of the ventilation will be determined based on visible chest expansion, adequate tidal volume and drawing of 6 successive ETCO2 waves.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Airway Management</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Air-Q intubating laryngeal airway mask</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Where Air-Q intubating laryngeal airway will be used for ventilation &amp; intubation through fiberoptic bronchoscope.
After complete muscle relaxation a suitable sized (according to the patient's weight and BMI) Air-Q will be lubricated inserted and the ventilator circuit will be connected to the device to ventilate the patient. The ventilator will be set with tidal volume 4-6 ml/kg at a respiratory rate 12-15 breath/minute to keep normocapnia (ETCO2=30-35 mmHg). Vitals (HR, ABP and O2 saturation) and ET CO2were recorded 5 minutes after device insertion.
Then intubation using the fiberoptic bronchoscope will be started through the supraglottic device, laryngeal view grade will be recorded, success of endotracheal intubation through the device and time of intubation (time starting from disconnection of the circuit from the device to use the fiberoptic brochoscope for intubation till tube insertion in the trachea).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ambu-Aura intubating laryngeal mask</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ambu-Aura intubating laryngeal mask will be used for ventilation &amp; intubation through fiberoptic bronchscope.
After complete muscle relaxation a suitable sized (according to the patient's weight and BMI) Ambu-Aura laryngeal mask will be lubricated inserted and the ventilator circuit will be connected to the device to ventilate the patient. The ventilator will be set with tidal volume 4-6 ml/kg at a respiratory rate 12-15 breath/minute to keep normocapnia (ETCO2=30-35 mmHg). Vitals (HR, ABP and O2 saturation) and ET CO2 will be recorded 5 minutes after device insertion.
Then intubation using the fiberoptic bronchoscope will be started through the supraglottic device, laryngeal view grade will be recorded, success of endotracheal intubation through the device and time of intubation (time starting from disconnection of the circuit from the device to use the fiberoptic brochoscope for intubation till tube insertion in the trachea).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Air-Q intubating laryngeal airway</intervention_name>
    <description>Air-Q intubating laryngeal airway will be used for ventilation &amp; intubation through fiberoptic bronchoscope.</description>
    <arm_group_label>Air-Q intubating laryngeal airway mask</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ambu-Aura intubating laryngeal mask</intervention_name>
    <description>Ambu-Aura intubating laryngeal mask will be used for ventilation &amp; intubation through fiberoptic bronchscope.</description>
    <arm_group_label>Ambu-Aura intubating laryngeal mask</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18-65 years old.

          -  Sex: both genders.

          -  With American society of anaesthesiologists (ASA) physical activity II.

          -  Scheduled for elective surgery under general anaesthesia requiring endotracheal tube.

          -  Class II obese patients (BMI 34.9 - 39.9 kg/m2).

          -  Surgery: short time procedures ≥ 60 minutes, ≤ 120 minutes e.g.: breast surgery, elbow
             or foot surgery.

        Exclusion Criteria:

          -  • Patient refusal.

               -  Patients with any respiratory tract abnormalities as laryngeal masses &amp; facial
                  deformities as fracture mandible.

               -  Patients with risk of pulmonary aspiration as in full stomach patients.

               -  Patients at risk of regurgitation of gastric content as in gastroesophageal
                  reflux disease (GERD) and pregnant females.

               -  Emergency operation.

               -  Patients with obstructive sleep apnea.

               -  Patients prepared for laparotomy or laparoscopic procedures.

               -  Patients with risk of bleeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bassant abdelhamid</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bassant abdelhamid</last_name>
    <phone>01224254012</phone>
    <email>bassantmohamed197@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Inas Farouk</last_name>
    <email>inasfarouk@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cairo university</name>
      <address>
        <city>Cairo</city>
        <zip>1772</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bassant abdelhamid</last_name>
      <phone>01224254012</phone>
      <email>bassantmohamed197@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Kim MS, Lee JH, Han SW, Im YJ, Kang HJ, Lee JR. A randomized comparison of the i-gel with the self-pressurized air-Q intubating laryngeal airway in children. Paediatr Anaesth. 2015 Apr;25(4):405-12. doi: 10.1111/pan.12609. Epub 2015 Jan 6.</citation>
    <PMID>25559870</PMID>
  </reference>
  <reference>
    <citation>Jagannathan N, Kozlowski RJ, Sohn LE, Langen KE, Roth AG, Mukherji II, Kho MF, Suresh S. A clinical evaluation of the intubating laryngeal airway as a conduit for tracheal intubation in children. Anesth Analg. 2011 Jan;112(1):176-82. doi: 10.1213/ANE.0b013e3181fe0408. Epub 2010 Nov 16.</citation>
    <PMID>21081777</PMID>
  </reference>
  <reference>
    <citation>Yahaya Z, Teoh WH, Dintan NA, Agrawal R. The AMBU® Aura-i™ Laryngeal Mask and LMA Supreme™: A Randomized Trial of Clinical Performance and Fibreoptic Positioning in Unparalysed, Anaesthetised Patients by Novices. Anesthesiol Res Pract. 2016;2016:4717061. Epub 2016 Oct 25.</citation>
    <PMID>27847515</PMID>
  </reference>
  <reference>
    <citation>Galgon RE, Schroeder KM, Han S, Andrei A, Joffe AM. The air-Q(®) intubating laryngeal airway vs the LMA-ProSeal(TM) : a prospective, randomised trial of airway seal pressure. Anaesthesia. 2011 Dec;66(12):1093-100. doi: 10.1111/j.1365-2044.2011.06863.x. Epub 2011 Aug 22.</citation>
    <PMID>21880031</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 7, 2019</study_first_submitted>
  <study_first_submitted_qc>December 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Bassant M. Abdelhamid</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>Air QTM intubating airway</keyword>
  <keyword>Ambu-Aura intubating laryngeal mask</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

